A functional variant of TLR10 modifies the activity of NFkB and may help predict a worse prognosis in patients with rheumatoid arthritis

Arthritis Research and Therapy

Volumn 18, Issue 1, 2016, Pages

  Torices, Silvia ^a   Julia, Antonio ^b   Muñoz, Pedro ^c   Varela, Ignacio ^d   Balsa, Alejandro ^e   Marsal, Sara ^b   Fernández Nebro, Antonio ^f   Blanco, Francisco ^g   López Hoyos, Marcos ^a   Martinez Taboada, Víctor ^a,h   Fernández Luna, Jose L ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Servicio Cantabro de Salud   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^g UNIVERSITY OF A CORUÑA   (Spain)

^h UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Infliximab; NFkB; Rheumatoid arthritis; TLR10 variant

Indexed keywords

ANTIBODY; ANTIGEN; CITRULLINATED PROTEIN ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; TOLL LIKE RECEPTOR 10; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; TLR10 PROTEIN, HUMAN;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DAS28; DISEASE SEVERITY; EUROPEAN LEAGUE AGAINST RHEUMATISM CRITERIA; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE ASSESSMENT; POLYMERASE CHAIN REACTION; PROGNOSIS; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; TLR10 GENE; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; BIOSYNTHESIS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; NF-KAPPA B; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTOR 10;

EID: 84990060552     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-016-1113-z     Document Type: Article

References (45)

1. + blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum. 2004;50(5):1457-67.
2. Pierer M, Rethage J, Seibl R, Lauener R, Brentano F, Wagner U, et al. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol. 2004;172(2):1256-65.
3. Gdor I, Zhu J, Loevsky B, Smolensky E, Friedman N, Sheves M, et al. Investigating excited state dynamics of salinixanthin and xanthorhodopsin in the near-infrared. Phys Chem Chem Phys. 2011;13(9):3782-7.
4. Wagner H. Endogenous TLR, ligands and autoimmunity. Adv Immunol. 2006;91:159-73.
5. Deighton K, Batterham RL, Stensel DJ. Appetite and gut peptide responses to exercise and calorie restriction: the effect of modest energy deficits. Appetite. 2014;81:52-9.
6. Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev Immunol. 2004;4(7):512-20.
7. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007;7(5):353-64.
8. Drexler SK, Foxwell BM. The role of Toll-like receptors in chronic inflammation. Int J Biochem Cell Biol. 2010;42(4):506-18.
9. Abu-Soud HM, Wu C, Ghosh DK, Stuehr DJ. Stopped-flow analysis of CO and NO binding to inducible nitric oxide synthase. Biochemistry. 1998;37(11):3777-86.
10. Oosting M, Cheng SC, Bolscher JM, Vestering-Stenger R, Plantinga TS, Verschueren IC, et al. Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proc Natl Acad Sci U S A. 2014;111(42):E4478-84.
11. Hasan U, Chaffois C, Gaillard C, Saulnier V, Merck E, Tancredi S, et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol. 2005;174(5):2942-50.
12. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol. 2002;168(9):4531-7.
13. Nagase H, Okugawa S, Ota Y, Yamaguchi M, Tomizawa H, Matsushima K, et al. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol. 2003;171(8):3977-82.
14. Mulla MJ, Myrtolli K, Tadesse S, Stanwood NL, Gariepy A, Guller S, et al. Cutting-edge report: TLR10 plays a role in mediating bacterial peptidoglycan-induced trophoblast apoptosis. Am J Reprod Immunol. 2013;69(5):449-53.
15. Guan Y, Ranoa DR, Jiang S, Mutha SK, Li X, Baudry J, et al. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. J Immunol. 2010;184(9):5094-103.
16. Abhishek A, Butt S, Gadsby K, Zhang W, Deighton CM. Anti-TNF-α agents are less effective for the treatment of rheumatoid arthritis in current smokers. J Clin Rheumatol. 2010;16(1):15-8.
17. Zhou H, Gu J, Lamont SJ, Gu X. Evolutionary analysis for functional divergence of the Toll-like receptor gene family and altered functional constraints. J Mol Evol. 2007;65(2):119-23.
18. Kuuliala K, Orpana A, Leirisalo-Repo M, Kautiainen H, Hurme M, Hannonen P, et al. Polymorphism at position +896 of the Toll-like receptor 4 gene interferes with rapid response to treatment in rheumatoid arthritis. Ann Rheum Dis. 2006;65(9):1241-3.
19. Radstake TR, Franke B, Hanssen S, Netea MG, Welsing P, Barrera P, et al. The Toll-like receptor 4 Asp299Gly functional variant is associated with decreased rheumatoid arthritis disease susceptibility but does not influence disease severity and/or outcome. Arthritis Rheum. 2004;50(3):999-1001.
20. Etem EO, Elyas H, Ozgocmen S, Yildirim A, Godekmerdan A. The investigation of Toll-like receptor 3, 9 and 10 gene polymorphisms in Turkish rheumatoid arthritis patients. Rheumatol Int. 2011;31(10):1369-74.
21. Coenen MJ, Enevold C, Barrera P, Schijvenaars MM, Toonen EJ, Scheffer H, et al. Genetic variants in Toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcome. PLoS One. 2010;5(12), e14326.
22. Requena T, Gazquez I, Moreno A, Batuecas A, Aran I, Soto-Varela A, et al. Allelic variants in TLR10 gene may influence bilateral affectation and clinical course of Meniere's disease. Immunogenetics. 2013;65(5):345-55.
23. Kutikhin AG. Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum Immunol. 2011;72(11):1095-116.
24. Stappers MH, Oosting M, Ioana M, Reimnitz P, Mouton JW, Netea MG, et al. Genetic variation in TLR10, an inhibitory Toll-like receptor, influences susceptibility to complicated skin and skin structure infections. J Infect Dis. 2015;212(9):1491-9.
25. Avila-Pedretti G, Tornero J, Fernandez-Nebro A, Blanco F, Gonzalez-Alvaro I, Canete JD, et al. Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis. PLoS One. 2015;10(4), e0122088.
26. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
27. Julia A, Domenech E, Ricart E, Tortosa R, Garcia-Sanchez V, Gisbert JP, et al. A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300. Gut. 2013;62(10):1440-5.
28. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-60.
29. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297-303.
30. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-75.
31. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 2003;31(13):3812-4.
32. Yue P, Li Z, Moult J. Loss of protein structure stability as a major causative factor in monogenic disease. J Mol Biol. 2005;353(2):459-73.
33. Lopez-Lasanta M, Julia A, Maymo J, Fernandez-Gutierrez B, Urena-Garnica I, Blanco FJ, et al. Variation at interleukin-6 receptor gene is associated to joint damage in rheumatoid arthritis. Arthritis Res Ther. 2015;17:242.
34. Inohara N, Ogura Y, Chen FF, Muto A, Nunez G. Human Nod1 confers responsiveness to bacterial lipopolysaccharides. J Biol Chem. 2001;276(4):2551-4.
35. Acosta-Colman I, Palau N, Tornero J, Fernandez-Nebro A, Blanco F, Gonzalez-Alvaro I, et al. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics. 2013;14(7):727-34.
36. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506(7488):376-81.
37. Govindaraj RG, Manavalan B, Lee G, Choi S. Molecular modeling-based evaluation of hTLR10 and identification of potential ligands in Toll-like receptor signaling. PLoS One. 2010;5(9), e12713.
38. Dai Y, Rahmani M, Pei XY, Dent P, Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood. 2004;104(2):509-18.
39. Cromartie WJ, Craddock JG, Schwab JH, Anderle SK, Yang CH. Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med. 1977;146(6):1585-602.
40. Regan T, Nally K, Carmody R, Houston A, Shanahan F, Macsharry J, et al. Identification of TLR10 as a key mediator of the inflammatory response to Listeria monocytogenes in intestinal epithelial cells and macrophages. J Immunol. 2013;191(12):6084-92.
41. Zheng B, Li Q, Wei C, Qin J, Shou T, Zhou R, et al. Lack of association of TLR4 gene Asp299Gly and Thr399Ile polymorphisms with rheumatoid arthritis in Chinese Han population of Yunnan Province. Rheumatol Int. 2010;30(9):1249-52.
42. Ma X, Liu Y, Gowen BB, Graviss EA, Clark AG, Musser JM. Full-exon resequencing reveals Toll-like receptor variants contribute to human susceptibility to tuberculosis disease. PLoS One. 2007;2(12), e1318.
43. Lazarus R, Raby BA, Lange C, Silverman EK, Kwiatkowski DJ, Vercelli D, et al. TOLL-like receptor 10 genetic variation is associated with asthma in two independent samples. Am J Respir Crit Care Med. 2004;170(6):594-600.
44. Alten R, van den Bosch F. Dose optimization of infliximab in patients with rheumatoid arthritis. Int J Rheum Dis. 2014;17(1):5-18.
45. Rajaraman P, Brenner AV, Neta G, Pfeiffer R, Wang SS, Yeager M, et al. Risk of meningioma and common variation in genes related to innate immunity. Cancer Epidemiol Biomarkers Prev. 2010;19(5):1356-61.